ASH 2017: Daratumumab in Intermediate- or High-Risk Smoldering Multiple Myeloma
According to updated data from the ongoing CENTAURUS trial, a multicenter phase II study presented by Craig C. Hofmeister, MD, of The Ohio State University, Columbus, and colleagues, at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 510), daratumumab was well tolerated in patients with intermediate- or high-risk smoldering multiple myeloma. The study centers on the objective that daratumumab may delay the progression of smoldering to symptomatic multiple myeloma.
A total of 123 patients were randomized to 1 of 3 treatment arms. The first arm was the long, intense dosing schedule (daratumumab administered weekly in cycle 1, every other week in cycles 2–3, every 4 weeks in cycles 4–7, and every 8 weeks up to cycle 20). The second arm was the intermediate dosing schedule (daratumumab administered weekly in cycle 1 and every 8 weeks up to cycle 20). The third arm was the short, intense dosing schedule (daratumumab administered every week for 1 cycle).
With a median follow-up of 9.6 months (range, 0–17.9 months), the overall response rate was numerically higher in the first arm than in the second and third arms. Median progression-free survival was not reached in any treatment arm. Hematologic treatment-emergent adverse events occurred in less than 10% of patients across all arms. The rate of grade 3/4 infection was less than or equal to 5% in all arms.
“These early results are encouraging, demonstrating the potential of daratumumab in tackling multiple myeloma, by treating smoldering multiple myeloma, a precancerous form of the disease,” noted the authors in a press release.